NCT05203419View on ClinicalTrials.gov

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

June 4, 2023

Study Completion Date

June 4, 2023

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

MHS552

MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

DRUG

Placebo

Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

Trial Locations (1)

10117

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY